Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01692301 · ClinicalTrials.gov registry record · Phase 2

Study of the Safety and Efficacy of LCZ696 on Arterial Stiffness in Elderly Patients With Hypertension

A Phase 2 study of Hypertension, sponsored by Novartis Pharmaceuticals.

Completed
Registry status
Phase 2
Development phase
454
Enrollment target
20
Study locations

NCT01692301 is a Phase 2 study of Hypertension that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 454 participants, below the 3,506-participant average among 470 other Hypertension trials with a reported enrollment target (87% lower). The trial reports 20 study locations across 13 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01692301, a Phase 2 study of Hypertension, has completed, sponsored by Novartis Pharmaceuticals.

COMPLETED
Registry status
Phase 2
Development phase
454 participants
Enrollment target
20
Study locations

Study Summary

The study examined the efficacy of LCZ696 in comparison to the ARB olmesartan on Central Aortic Systolic Blood Pressure (CASP) and other measures of central hemodynamics and arterial stiffness in elderly patients with an elevated systolic blood pressure (SBP) and widened pulse pressure (PP).

Conditions Studied

Hypertension

Interventions

  • DRUG LCZ696
  • DRUG Olmesartan
  • DRUG LCZ696 matching placebo
  • DRUG Olmesartan matching placebo
  • DRUG amlodipine

Study Locations (20)

Other

  • Novartis Investigative Site - Barranquilla
  • Novartis Investigative Site - Paris
  • Novartis Investigative Site - Berlin
  • Novartis Investigative Site - Nuremberg

Texas

  • Novartis Investigative Site - Houston
  • Novartis Investigative Site - Lake Jackson
  • Novartis Investigative Site - Pasadena

Mississippi

  • Novartis Investigative Site - Belzoni
  • Novartis Investigative Site - Jackson

Buenos Aires

  • Novartis Investigative Site - Caba
  • Novartis Investigative Site - Ramos Mejía

Florida

  • Novartis Investigative Site - Clearwater

Illinois

  • Novartis Investigative Site - Chicago

Maryland

  • Novartis Investigative Site - Baltimore

Missouri

  • Novartis Investigative Site - St Louis

Trial Details

FieldValue
Enrollment Target 454 participants
Start Date 2012-12
Est. Completion 2015-04
Phase Phase 2

Sponsor

Novartis Pharmaceuticals

1,375 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01692301

The ClinicalTrials.gov registry entry for NCT01692301 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 454 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,506-participant average among 470 other Hypertension trials with a reported enrollment target (87% lower). The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Hypertension appearing as the primary indexed condition, and to 5 interventions - of which LCZ696 is the first listed.

NCT01692301 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Other, Texas, Mississippi.

Frequently Asked Questions

What is clinical trial NCT01692301 about?

NCT01692301 is a clinical study titled "Study of the Safety and Efficacy of LCZ696 on Arterial Stiffness in Elderly Patients With Hypertension". The study examined the efficacy of LCZ696 in comparison to the ARB olmesartan on Central Aortic Systolic Blood Pressure (CASP) and other measures of central hemodynamics and arterial stiffness in elderly patients with an elevated systolic blood pressure (SBP) and widened pulse pressure (PP).

What is the current status of trial NCT01692301?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 454 participants. The study started on 2012-12. Estimated completion is 2015-04.

What conditions does trial NCT01692301 study?

This clinical trial studies the following conditions: Hypertension.

What interventions are being tested in trial NCT01692301?

The interventions under investigation include: LCZ696 (DRUG), Olmesartan (DRUG), LCZ696 matching placebo (DRUG), Olmesartan matching placebo (DRUG), amlodipine (DRUG).

Who is sponsoring clinical trial NCT01692301?

This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01692301 being conducted?

This trial has 20 study locations across Florida, Illinois, Maryland, Mississippi, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Hypertension

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Hypertension

All registered trials for this condition

Florida

All trials with a study site in Florida

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.